The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2022 | The importance of CAR-T therapy in myeloma and redefining patient risk
In this video, Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, shares some insights into the promise of CAR-T therapy for the future treatment of multiple myeloma, and the need for CAR-T therapies to be approved in European countries. Dr Cerchione also highlights the importance of defining the best sequencing for CAR-T therapy and bispecific antibodies, as well as the importance of redefining risk in patients. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
